report ge close usher new era
tom joyc retir rainer blair name ceo
report result close earlier expect reason
announc ceo tom joyc retir year sept rainer
blair evp life scienc divis succeed mr joyc stay advis
surpris close transform ge lifesci
call cytiva deal weve known mr blair sinc appoint pre
sciex busi think solid choic run new era
surpris pre-announc result
per pre-announc link report rev vs
our/street organ growth gross margin
y/i adj op margin y/i cytiva relat cost
see varianc tabl pg adj ep street
diagnost dx led core sale growth life scienc ls
grew environment appli solut ea
take hit remain posit
april saw core revenu growth slightli y/i may/jun weaker
see pro forma core revenu growth includ cytiva flat
ex-cytivia estimate core declin around vs estimate like due larger
expect instrument headwind lower routin diagnost anatom
patholog volum updat actual result await management
commentari color formal updat near-term est
said look beyond crisi close cytiva deal
believ well-posit improv core growth given life
scienc research bioprocess molecular dx exposur updat year
revenu margin assumpt rais po still base dcf
use wacc termin growth rate reiter buy rate
host call today et dial-in code
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
one largest diversifi
product includ analyt instrument
consum life scienc research
diagnost dental instrument consum
equip servic use water qualiti
test product identif compani
known lead brand across mani
vertic strong manag team
record superior execut
follow spin-off industrial-them
becam one premier stand-
alon life scienc compani acquisit
ge life scienc call cytiva busi
divestitur lag dental segment
transform compani
profil free cash flow gener potenti
tabl overview perform
po base dcf analysi assum wacc termin growth rate
believ deal transform boost organ
revenu growth strong accentu alreadi strong free cash flow gener
downsid risk po fx risk econom macro risk cyclic exposur
geopolit risk reduct fund custom consolid slowdown
bioprocess demand competit risk deal integr risk headwind
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
